Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

This study has been completed.
Eli Lilly and Company
Information provided by:
McMaster University Identifier:
First received: September 14, 2005
Last updated: September 8, 2006
Last verified: March 2006

September 14, 2005
September 8, 2006
June 2000
Not Provided
Clinical Global Impression (CGI)-Improvement Scale ≤ 2
Same as current
Complete list of historical versions of study NCT00182507 on Archive Site
CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale
Same as current
Not Provided
Not Provided
Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania

Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been unsuccessful. Tics/Tourrettes’ Syndrome (TS) is a disorder, which appears to be related to TTM, but is treated with a different class of medications than used in OCD, namely antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine in the treatment of hair pulling.

Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Drug: Olanzapine
Not Provided
Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010 Oct;71(10):1336-43. doi: 10.4088/JCP.09m05114gre. Epub 2010 Apr 20.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2006
Not Provided

Inclusion Criteria:

  • primary DSM-IV trichotillomania; CGI-Severity ≥ 4

Exclusion Criteria:

  • Any other Axis I primary diagnosis; CGI-S < 4; current comorbid: OCD, MDD, alcohol or substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or dementia; current pregnancy/lactation; current suicidality or homicidality; major medical problems or clinically unstable medical disease; hx of: seizures, stroke or head trauma; prior use of neuroleptics
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Hamilton Health Sciences Corporation
Eli Lilly and Company
Principal Investigator: Michael A Van Ameringen, MD, FRCPC Hamilton Health Science, McMaster Univeristy Medical Centre
McMaster University
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP